Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2014

View Archived Issues

AbbVie disclose novel glucocorticoid receptor modulators

Prana Biotechnology reports preliminary data from phase II IMAGINE trial

First patient enrolled in phase III AN-2728 trial

Novel ultra-fast vaccine formulation shows safety and efficacy in phase IIb trial

Clinigen acquires Savene from SpePharm

Heron Therapeutics initiates label-expansion study of Sustol

Sorrento Therapeutics begins dosing in pivotal bioequivalence study of Cynviloq

Galectin Therapeutics reports biomarker results from first cohort in phase I trial in NASH

Anavex obtains exclusive rights to AF-710B to strengthen Alzheimer's pipeline

NIH funding to progress isradipine into phase III for Parkinson's disease

Jazz Pharmaceuticals and Gentium announce European launch of Defitelio

Clinical safety of abuse-deterrent analgesic formulations

Brazilian group prepares new agents for cancer

Halozyme Therapeutics' CONSISTENT 1 study of Hylenex meets primary endpoint

New MCHR-1 antagonists presented by Bristol-Myers Squibb

Boehringer Ingelheim patents novel sGC activators

FDA grants orphan drug status to Graspa for AML

Janssen submits NDA to the FDA for darunavir/cobicistat fixed-dose combination tablet

LCZ-696 trial in chronic heart failure closes early based on interim results

MicroRNAs may be biomarkers of drug-induced pancreatic injury

Lenvatinib receives orphan drug status from the FDA for two indications

OPKO Health launches 4Kscore test for prostate cancer

Guselkumab is an effective, well-tolerated therapy for psoriasis according to phase II results

Array CGH-SNP analysis may identify undetected cases of myelodysplastic syndromes

GSK ends MAGRIT study of MAGE-A3 cancer immunotherapeutic

FDA advisory committee recommends approval of Afrezza

FDA approves Oralair

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...